Abbott (ABT) acquires Cardiovascular Systems (CSII) in 'brilliant move'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
CSII Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Sale of Cardiovascular Systems, Inc. to Abbott Laboratories
February 9, 2023 9:29 AM ESTMONSEY, N.Y., Feb. 09, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of Cardiovascular Systems, Inc. (Nasdaq: CSII) (CSII) acted in the best interests of CSII shareholders in approving the sale of CSII to Abbott Laboratories (Abbott) for $20.00 per share in cash.
If you remain a CSII shareholder and have questions about your legal rights, you may contact our firm at the following link to discuss your options at no charge:
... MoreCardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results
February 8, 2023 6:12 PM ESTST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022.
Second Quarter Financial Highlights
CSIs fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%.
Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due... More
Abbott to Acquire Cardiovascular Systems, Inc.
February 8, 2023 6:05 PM ESTAbbott will gain an innovative, complementary solution in treating vascular disease through CSI's leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flowCSI's offering will support Abbott's ability to provide better care for patients with peripheral and coronary artery disease
ABBOTT PARK, Ill. and ST. PAUL, Minn., Feb. 8, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device... More
